Ann L White

Summary

Affiliation: University of Southampton
Country: UK

Publications

  1. doi request reprint FcγRΙΙB controls the potency of agonistic anti-TNFR mAbs
    Ann L White
    Antibody and Vaccine Group, MP88, Cancer Sciences Unit, Faculty of Medicine, Southampton University Hospital, Tremona Road, Southampton, SO16 0XA, UK
    Cancer Immunol Immunother 62:941-8. 2013
  2. doi request reprint Interaction with FcγRIIB is critical for the agonistic activity of anti-CD40 monoclonal antibody
    Ann L White
    Division of Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton SO16 6YD, United Kingdom
    J Immunol 187:1754-63. 2011
  3. pmc Ligation of CD11c during vaccination promotes germinal centre induction and robust humoral responses without adjuvant
    Ann L White
    Tenovus Research Laboratory, Cancer Sciences Division, Southampton University School of Medicine, General Hospital, Southampton, UK
    Immunology 131:141-51. 2010
  4. doi request reprint Conformation of the human immunoglobulin g2 hinge imparts superagonistic properties to immunostimulatory anticancer antibodies
    Ann L White
    Cancer Sciences Unit, Faculty of Medicine, University of Southampton, Tremona Road, Southampton SO16 6YD, UK Electronic address
    Cancer Cell 27:138-48. 2015
  5. doi request reprint Fcγ receptor dependency of agonistic CD40 antibody in lymphoma therapy can be overcome through antibody multimerization
    Ann L White
    Antibody and Vaccine Group, Cancer Sciences Unit, University of Southampton Faculty of Medicine, Southampton SO16 6YD, United Kingdom
    J Immunol 193:1828-35. 2014
  6. doi request reprint FcγRIIB as a key determinant of agonistic antibody efficacy
    Ann L White
    Cancer Sciences Unit, Antibody and Vaccine Group MP88, Faculty of Medicine, Southampton University, Tremona Road, Southampton, SO16 6YD, UK
    Curr Top Microbiol Immunol 382:355-72. 2014
  7. doi request reprint CD11c provides an effective immunotarget for the generation of both CD4 and CD8 T cell responses
    Fernanda V V Castro
    Tenovus Research Laboratory, Cancer Sciences Division, Southampton University School of Medicine, Southampton, UK
    Eur J Immunol 38:2263-73. 2008

Collaborators

Detail Information

Publications7

  1. doi request reprint FcγRΙΙB controls the potency of agonistic anti-TNFR mAbs
    Ann L White
    Antibody and Vaccine Group, MP88, Cancer Sciences Unit, Faculty of Medicine, Southampton University Hospital, Tremona Road, Southampton, SO16 0XA, UK
    Cancer Immunol Immunother 62:941-8. 2013
    ..Thus, modifying the A/I binding ratio of human IgG Fc can be used to optimise different types of therapeutic activity by enhancing cytotoxic or hyper-crosslinking function...
  2. doi request reprint Interaction with FcγRIIB is critical for the agonistic activity of anti-CD40 monoclonal antibody
    Ann L White
    Division of Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton SO16 6YD, United Kingdom
    J Immunol 187:1754-63. 2011
    ..In conclusion, we demonstrate an essential cross-linking role for the inhibitory FcγRIIB in anti-CD40 immunostimulatory activity and suggest that isotype will be an important issue when optimizing reagents for clinical use...
  3. pmc Ligation of CD11c during vaccination promotes germinal centre induction and robust humoral responses without adjuvant
    Ann L White
    Tenovus Research Laboratory, Cancer Sciences Division, Southampton University School of Medicine, General Hospital, Southampton, UK
    Immunology 131:141-51. 2010
    ..They also point to an interesting role for CR4 on DC in triggering B cells during humoral immunity...
  4. doi request reprint Conformation of the human immunoglobulin g2 hinge imparts superagonistic properties to immunostimulatory anticancer antibodies
    Ann L White
    Cancer Sciences Unit, Faculty of Medicine, University of Southampton, Tremona Road, Southampton SO16 6YD, UK Electronic address
    Cancer Cell 27:138-48. 2015
    ..This provides the exciting opportunity to engineer clinical reagents with defined therapeutic activity regardless of FcγR expression levels in the local microenvironment. ..
  5. doi request reprint Fcγ receptor dependency of agonistic CD40 antibody in lymphoma therapy can be overcome through antibody multimerization
    Ann L White
    Antibody and Vaccine Group, Cancer Sciences Unit, University of Southampton Faculty of Medicine, Southampton SO16 6YD, United Kingdom
    J Immunol 193:1828-35. 2014
    ..These findings have important translational implications, as humans, unlike mice, do not have IgG that binds strongly to FcγRIIB; therefore FcγR-independent derivatives represent an attractive therapeutic option. ..
  6. doi request reprint FcγRIIB as a key determinant of agonistic antibody efficacy
    Ann L White
    Cancer Sciences Unit, Antibody and Vaccine Group MP88, Faculty of Medicine, Southampton University, Tremona Road, Southampton, SO16 6YD, UK
    Curr Top Microbiol Immunol 382:355-72. 2014
    ..In this review we highlight the key role of FcγRIIB in regulating agonistic mAb, detail the likely mechanism of action and propose new ways in which this information may be exploited therapeutically. ..
  7. doi request reprint CD11c provides an effective immunotarget for the generation of both CD4 and CD8 T cell responses
    Fernanda V V Castro
    Tenovus Research Laboratory, Cancer Sciences Division, Southampton University School of Medicine, Southampton, UK
    Eur J Immunol 38:2263-73. 2008
    ..These results suggest that targeting antigen via CD11c offers a previously unappreciated strategy for vaccine development which, unlike most targets, delivers robust responses of both CD4 and CD8 T cells...